Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Citrobacter”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 937 records · Page 52Linked to original sources
PubMed1986

[In vitro activity of carumonam (RO 17-2301) on hospital bacteria].

Minimal inhibitory concentrations (MICs) of carumonam (RO 17-2301), a new synthetic antibacterial agent of the monobactam group, were evaluated by agar dilution for 399 hospital isolates. RO 17-2301 was inactive against Gram positive and anaerobic bacteria. Most Enterobacteriaceae were inhibited by concentrations less than 1 microgram/ml, with mode MICs approximating 0.03 micrograms/ml except for Providencia (0.016), Citrobacter (0.06), Serratia (0.06) and Enterobacter (0.12). A few strains, most of which were Enterobacter or Citrobacter, had high MICs (greater than 8 micrograms/ml). RO 17-2301 was less active against Pseudomonas aeruginosa (mode MIC 2 micrograms/ml) and Acinetobacter (mode MIC 8-16 micrograms/ml). Haemophilus influenzae sp. were sensitive to RO 17-2301 (mode MIC 0.12-0.25), regardless of beta-lactamase production status; MICs ranged from 0.06 to 0.25 micrograms/ml for Meningococci, and from 0.008 to 0.06 for Gonococci except for a few strains that had higher MICs (0.25 to 0.5 and even 4 micrograms/ml). In vitro activity of RO 17-2301 on Gram negative bacteria proved similar to that of third-generation cephalosporins; cefotaxime-resistant Enterobacteriaceae are resistant to RO 17-2301.

Anti-Bacterial Agents↗
PubMed1987

[Practical recommendations for examining the pulmonary pleura of fetuses and newborn infants using contact microscopy].

It has been found that the pleura visceralis of fetuses and neonates is consistently involved in inflammatory processes occurring in pneumonias caused by Gram-negative organisms (Citrobacter sp., Escherichia coli, Klebsiella sp., Serratia marcescens) and may display signs of infection when the pneumonia is not yet apparent. This property of the pleura as a filtration membrane may help the pathologist in the early diagnosis of infectious disorders in neonates. Recommendations are given on the excision of pulmonary pleura and the staining of its preparations for contact microscopy whereby these can be examined during or shortly after the autopsy. Morphologic features of the infections caused by the indicated organisms are detailed. Citrobacter infections, for example, show a preponderance of macrophage responses, Klebsiella-caused lesions are characterized by involvement of the lymphatic bed, while those due to S. marcescens have hemolysis in the lung tissue and pleura as their main feature.

Bacterial Infections↗
PubMed1986

[Effect of cefminox on bacterial flora in human adult feces].

Cefminox (CMNX), a new cephamycin, was administered by one shot intravenous injection twice daily with a dose of 1,000 mg each time for 5 days to seven healthy male volunteers whose ages ranged from 21 to 28 years (mean: 25 years) and body weights were from 60 to 92 kg mean: 72 kg). The effect of the drug on fecal bacterial flora was investigated and the concentrations of the drug in feces were measured on 5th day before the treatment, on 0, 3rd, and 5th day (the final day of the treatment) during the treatment, and on 3rd, 5th, and 10th day after the treatment. Antibiotic susceptibility tests of CMNX, cefmetazole (CMZ) and cefotaxime (CTX) against several strains of organisms isolated from feces of the seven volunteers were performed. Clinical adverse reactions and effect on laboratory examinations were also investigated. The results of the study are described as follows. Among Enterobacteriaceae, populations of E. coli, Klebsiella sp. and Citrobacter sp. temporarily disappeared during the treatment of CMNX. After 5-day-treatment, that of Citrobacter sp. transiently increased and the isolation of Enterobacter sp. increased during treatment and up to 5 days after treatment, while those of Proteus sp., H. alvei, or Serratia sp. did not show a definite change. The mean Enterobacteriaceae population in general was 10(8) to 10(9) cells/g feces, showing almost no variation, on all examination days except 5th day during treatment when these organisms were not isolated from only one subject. No remarkable change was not found in populations of other isolated organisms including Gram-negative bacilli; Aeromonas sp., Pseudomonas sp. and Acinetobacter sp., and Gram-positive bacteria; Staphylococcus sp., Enterococcus sp., Micrococcus sp. and Candida sp. Among anaerobes, the mean population of Bacteroides sp. was 10(10) to 10(11) cells/g feces, showing almost no variation, and C. difficile was not isolated from any subject, however the toxin was detected in samples from 5 of 7 subjects; one subject showed always positive for toxin on all examination days; 1 on 5th day during treatment to 10th day after treatment; 2 on 5th and 10th day after treatment, and 1 only on 10th day after treatment.(ABSTRACT TRUNCATED AT 400 WORDS)

Abdomen↗
PubMed1984

[Laboratory and clinical studies of ceftriaxone in the pediatric field].

The authors have carried out the laboratory and clinical studies of ceftriaxone (Ro 13-9904, CTRX) and obtained the following results. The antibacterial activities of CTRX against the clinical isolates of S. aureus, E. coli, K. pneumoniae, E. cloacae, E. aerogenes, S. marcescens, Citrobacter sp. and P. aeruginosa were measured by the agar dilution method with inoculum size of 10(6) cells/ml. The susceptibility distribution of S. aureus to CTRX ranged from 0.2 to 12.5 micrograms/ml, and the peak of distribution was 3.13 micrograms/ml. The peak of susceptibility distribution of E. coli and K. pneumoniae were 0.1 microgram/ml or lower, and the distribution of E. aerogenes and E. cloacae ranged from 0.1 to 100 micrograms/ml, Citrobacter sp. and S. marcescens, from 0.1 to 12.5 micrograms/ml and that of P. aeruginosa, from 0.39 to 100 micrograms/ml or more. For pharmacokinetic study, CTRX was given in a single dose of 10 mg/kg in 1 child and 20 mg/kg in 2 children by drip infusion for 1 hour. After drip infusion of CTRX in a single dose of 10 mg/kg, the peak serum level was 61.4 micrograms/ml on completion of the infusion, and 8.43 micrograms/ml at 12 hours. Half-life time was 4.6 hours. With drip infusion of CTRX in a single dose of 20 mg/kg, the peak serum level was 105.5 micrograms/ml on completion of the infusion, and 19.1 micrograms/ml at 12 hours. Half-life time was 8.7 hours. CTRX was effective all cases out of 8 cases with bacterial infection. No side effect was observed except for elevation of serum GOT in 2 cases and eosinophilia in 1 case.

Bacteria↗
PubMedDate not supplied

[Presence of resistance factors to antibiotics in multiresistant enterobacteria].

The present study was carried out with 111 multiresistant pathogenic strains of enterobacterias isolated from different sources with increased resistance to three or more antibiotics. Among the identified species are included E. coli, Shigella sp., Salmonella oranienburg, Klebsiella pneumoniae and Citrobacter freundii. In general, the minimal inhibitory concentration of antibiotics was above 100 microgram/ml and in some cases it was superior to 1000 microgram/ml. Resistance transfer factors were detected in 72% of the strains; 33% movilized the complete pattern of resistance and 67% did it partially because some of the determinants were not transfered. The Citrobacter strains show a high frequency of transference (10(-1)), while for the others species it was in the order of 10(-2)--10(-3). The use of a multi-inoculator allows to perform in a simple way the preliminar evaluation about the presence or absence of R transfer factors in multiresistant strains. This technique has shown good correlation with the data obtained by the usual dilution and plating method.

Animals↗
PubMed1984

[Resistance of Enterobacteria to cefotaxime and lamoxactam at the Pitié-Salpêtrière Hospital in 1982].

Systematic collection of data on every Enterobacteriaceae clinical isolate cultured in the Central Bacteriology Laboratory allowed comparison of the percentage of cefotaxim (CTX) and moxalactam ( MOX ) intermediate or resistant (IR) strains among the 8 199 Enterobacteriaceae isolated in 1982 and the 5 032 Enterobacteriaceae isolated in 1980. In 1982, IR rates were 2% to CTX and 0.6% to MOX . Among the 166 strains IR to CTX, 28% were also IR to MOX . Two strains only were IR to MOX but not to CTX. No E. coli, P. mirabilis or Klebsiella strains IR to CTX or MOX were isolated. On the opposite, percentages of strains IR to CTX or MOX were respectively 2.5 and 0 for indole positive Proteus, 6 and 3.6 for Enterobacter, 7.4 and 0.5 for Serratia and 17.2 and 2.5 for Citrobacter. Strains IR to CTX or MOX represented 3.3%, 2.5% and 1% of Enterobacteriaceae isolated from pus, urine and blood cultures, and 4.7%, 2.2% and 1.3% of those isolated in urology, surgery and medicine. Between 1980 and 1982, there was a simultaneous increase in the consumption of CTX and MOX (10 fold) and in the percentage of Enterobacteriaceae IR to CTX (2 fold); this last involved Serratia (9 fold) more than Citrobacter (3 fold) and spared Enterobacter.

Cefotaxime↗
PubMed1984

[Sensitivity to fosfomycin of bacteria isolated at the Pitié-Salpétrière Hospital in 1982 and 1983].

Susceptibility of 16 056 strains isolated in 1982 and 1983 to fosfomycin (FOS) was tested with Mueller-Hinton medium and discs 50 micrograms FOS + 25 micrograms glucose-6-phosphate (G6P) (cutoff diameter 14 mm). For 3 411 strains, inhibition zone diameters were recorded. Almost all E. coli, Citrobacter, Salmonella and S. aureus were susceptible to FOS as well as 70% of Serratia, E. cloacae, P. mirabilis and 50% of Klebsiella and Enterobacter sp. Only 27% of P. aeruginosa, 20% of indole positive Proteus and 8% of Acinetobacter were sensitive to FOS. E. coli, Citrobacter and S. aureus seem to exhibit the highest susceptibilities to FOS. Sensitivity rates of E. cloacae, Serratia, P. aeruginosa, and especially Klebsiella seemed slightly underestimated by the disk diffusion method, but differentiation between susceptible and resistant strains was facilitated by rating as susceptible those strains with inhibition zone diameters between 12 and 14 mm. This method also seemed to underrate the sensitivity of susceptible Enterobacteriaceae, probably because of inadequate G6P concentrations at this point of the disk.

Acinetobacter↗
PubMed1984

Inhibitory and bactericidal activities of amifloxacin, a new quinolone carboxylic acid, compared with those of seven other antimicrobial agents.

The activity of amifloxacin, a new quinolone carboxylic acid compound, against 147 strains of microorganisms was studied and was compared with the activities of cinoxacin, trimethoprim, amikacin, and four beta-lactam antimicrobials. The minimal concentration at which 90% of strains were inhibited by amifloxacin was lowest for Escherichia coli and Klebsiella sp (less than or equal to 0.125 microgram/ml), followed by Proteus sp (less than or equal to 0.25 microgram/ml), Enterobacter sp and Citrobacter sp (less than or equal to 0.5 microgram/ml), Providencia sp (less than or equal to 2 micrograms/ml), and Pseudomonas aeruginosa, Serratia sp, and Acinetobacter calcoaceticus var anitratus (less than or equal to 8 micrograms/ml). When compared with the ranges of activity of seven reference antimicrobials, the range of amifloxacin activity was lowest for P aeruginosa, Citrobacter sp, Proteus sp, and A calcoaceticus var anitratus and similar to aztreonam's activity against Enterobacter sp. For amikacin-resistant P aeruginosa, the minimal inhibitory concentrations (MICs) of amifloxacin ranged from 1 to 16 micrograms/ml. The MICs and minimal bactericidal concentrations (MBCs) of amifloxacin were similar. For all strains tested, microbial susceptibilities to amifloxacin were greater than those to currently available oral antimicrobial drugs, such as cinoxacin and trimethoprim.

Anti-Bacterial Agents↗
PubMed1976

[Serological analysis of two complex Salmonella respectively Arizona O-groups (Salmonella O:48 and O:64 - Arizona O:5 and O:29) with the object of combining them into one Salmonella O-group 48 within the Kauffmann-White-schema (author's transl)].

In 1963 KAUFFMANN divided O-group Y (= O:48) of the KAUFFMANN-WHITE-Schema into 3 sub-groups, e.g. 481, 482 - S. dahlem; 481, 482, 483 - S. djakarta; 481, 483, 484 = Citrobacter no. 2624/36. He also recommended the use of the two serotypes S. dahlem and S. djakarta for the preparation of a diagnostic group-serum. At that time, serological relations- especially O-antigenic relations (and even some identities) - between the separate Salmonella and Arizona genera were known, viz. between the Salmonella group 0:48 and the Arizona group O:5. It has now been found that there exist also close serological relations between the Salmonella O-groups 48 and 64 on the one hand and to the corresponding Arizona O-groups 5 and 29 on the other hand, in connection with which the special factor 484 defined by KAUFMANN in the Citrobacter culture no. 2624 embraces the whole Salmonella group O:64 (= Arizona group O:29). Therefore, every Salmonella O:64 strain and Arizona O:29 serotype respectively can be agglutinated with factorserum 484, defined by KAUFFMANN. A special O:64 serum is no longer required. The Salmonella antigen 64 (Ar. 29 or 5.29) has a rule the partial antigens 481, 483, 484 (= Ar. 5,29). Only a few serotypes do not possess factor 483; their components are 481 and 484 (= Ar. 29). The evidence of our findings demonstrates that the Salmonella O-group 64 (= Arizona 29) should be combined with O-group 48 (Ar. 5) and erased from the original Kauffmann-White-Schema and the Arizona Antigenic Schema to avoid a wrong diagnosis.

Absorption↗
PubMedDate not supplied

Antibacterial activity of aztreonam: a synthetic monobactam. A comparative study with thirteen other antibiotics.

The in vitro activity of aztreoman (SQ 26, 776), a new monocyclic beta-lactam antimicrobial agent, was determined against 1720 bacteria, all clinical isolates, and compared with that of thirteen beta-lactam and aminoglycoside antibiotics. Aztreonam inhibited 90% of Citrobacter diversus, Citrobacter freundii, Enterobacter agglomerans, E. coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus morganii, Proteus rettgeri, Proteus vulgaris and Salmonella sp. by less than or equal to 0.4 micrograms ml-1. This activity was superior to moxalactam, piperacillin, cefamandole, cefoperazone, cefoxitin, cefsulodin, ceftazidime and aminoglycoside antibiotics. Aztreonam was as active as moxalactam against Enterobacter aerogenes, Enterobacter cloacae and Shigella species. Pseudomonas aeruginosa strains resistant to moxalactam, piperacillin, cefamandole, cefoperazone, cefotaxime, cefoxitin, cefsulodin and ceftazidime were inhibited by aztreonam 50% by 6.3 micrograms ml-1 and 90% by 16 micrograms ml-1. Aztreonam was as active as ceftazidime against Serratia marcescens, all strains were inhibited by 3.1 micrograms ml-1 and 90% by 1.6 micrograms ml-1. There was no major difference between MBC and MIC values of aztreonam and the effect of inoculum size upon MIC values was observed at 10(7) CFU.

Anti-Bacterial Agents↗
PubMed1982

[Susceptibilities of clinical isolates to aminoglycoside antibiotics. Susceptibility of clinical isolates from patients with complex and refractory infections].

Four hundred strains (13 species, 8 genera) were obtained from patients with complicated and intractable infections. The antibiotic sensitivities of these isolates were determined in relation to aminoglycoside (AGs) (GM, DKB, AMK, HBK), beta-lactam (SBPC, PIPC, CMZ), and FOM. 1. The frequency of clinical isolates that were resistant to GM and DKB in this study was high level in the case of S. aureus, Enterobacter spp., S. marcescens, Proteus spp. (indole positive) and P. aeruginosa. And some of them were also resistant to AMK and HBK. However HBK had potent antibacterial activity to S. aureus. The inactivating enzyme contributing to AGs resistance was AAC for almost Gram-negative bacillis and APH + AAC for S. aureus. But AGs was not permeable only to P. maltophilia. 2. Almost similar resistant patterns were seen to SBPC and PIPC. However, the frequency of resistant strains of S. aureus to SBPC was less than one of PIPC, while that of Citrobacter spp. to PIPC was less than SBPC. Among of other bacteria, P. aeruginosa and Proteus spp. (indole positive) had moderate sensitivity to SBPC and PIPC. 3. CMZ had poor antibacterial activity to Enterobacter spp. and S. marcescens and no activity to P. aeruginosa. It had moderate activity to Citrobacter spp. and potent activity to S. aureus, E. coli, K. pneumoniae and Proteus spp. (indole positive). 4. FOM had antibacterial activity to all the bacteria tested. Almost FOM-sensitive bacteria had moderate MICs (6.25-25 micrograms/ml).

Aminoglycosides↗
PubMed1981

[Quantitative and species composition of conditionally-pathogenic microorganisms of the families Enterobacteriaceae and Pseudomonadaceae in healthy subjects and intestinal dysbacteriosis].

The spread and quantitative content of opportunistic microorganisms belonging to the families Enterobacteriaceae and Pseudomonadaceae in clinically healthy persons and in somatic patients with intestinal dysbacteriosis were studied. Opportunistic enterobacteria were shown to be widely spread in healthy persons (K. pneumoniae in 45%, Citrobacter in 44%, E. aerogenes in 17%, E. cloaceae in 11%). In clinically healthy persons most of these cultures (72.3%) were detected in an amount not exceeding 1 X 10(4) organisms per 1 g of feces, while in patients with intestinal dysbacteriosis opportunistic enterobacteria were detected in most cases (70.9%) in an amount of 1 X 10(5)--1 X 10(8) organisms per 1 g of feces. The results of this study suggest that the presence of the opportunistic enterobacteria K. pneumoniae, Citrobacter, E. aerogenes and E. cloaceae in an amount not exceeding 1 X 10(4) organisms per 1 g of feces is normal for healthy persons, while the increase of their presence in the intestine to 1 X 10(6)--1 X 10(8) is indicative of intestinal dysbacteriosis.

Abdomen↗
PubMed1980

Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns.

The antimicrobial activity of netilmicin, gentamicin, sisomicin, tobramycin and amikacin was determined by means of the microdilution test. 1000 fresh isolates of strains of Staphylococcus aureus, Pseudomonas aeruginosa and 7 species of the Enterobacteriaceae were tested. The activities were compared and cross-resistances were analyzed which appeared among the various drugs. Against amikacin, only 0.5% of all strains (3 P. aeruginosa, 1 S. aureus, 1 P. mirabilis) were resistant. Of the other drugs, netilmicin was the most active drug against S. aureus, Klebsiella spp., Enterobacter spp. and Escherichia coli. Against E. coli, too, sisomicin showed its best activity, and further against Citrobacter spp., Proteus spp. and P. aeruginosa. A total of 12% of all pathogens was gentamicin-resistant. With one exception, these pathogens showed cross-resistance to at least one of the other drugs. In 39% of the cases a cross-resistance between gentamicin and tobramycin was noted, in 26% a gentamicin-tobramycin-sisomicin cross-resistance, in 17% gentamicin-tobramycin-sisomicin-netilmicin cross-resistance, in 11% a gentamicin-sisomicin-netilmicin cross-resistance. A complete cross-resistance was observed between gentamicin and sisomicin with S. aureus, Serratia spp. and Proteus mirabilis, between gentamicin and tobramycin with E. coli, Citrobacter spp. and Enterobacter spp.

Amikacin↗
PubMed1993

In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.

The in vitro activity of nine fluoroquinolones, enoxacin, norfloxacin, ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, sparfloxacin, fleroxacin and levofloxacin, and two earlier quinolones, nalidixic acid and pipemidic acid, against 1,346 bacterial strains isolated clinically between 1989 and 1990, was evaluated by agar dilution method. The bacteria studied were Staphylococcus aureus (including methicillin-susceptible and -resistant strains), Staphylococcus epidermidis, Enterococcus species (including high-level gentamicin-resistant strains), Escherichia coli, Salmonella species, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Citrobacter spp., Pseudomonas aeruginosa, Pseudomonas cepacia, Acinetobacter baumannii, and Bacteroides fragilis. In contrast to the moderate to poor activity of two earlier quinolones, the fluoroquinolones acted well against most Enterobacteriaceae and A. baumannii. The minimum inhibitory concentrations for 90% of the drug strains (MIC90s) were < 1 microgram/mL against most tested species. Ciprofloxacin, tosufloxacin, sparfloxacin, and levofloxacin were more effective against multi-drug-resistant nosocomial pathogens. All fluoroquinolones assayed were very active against methicillin-susceptible S. aureus, with MIC90s < or = 1 microgram/mL. For methicillin-resistant strains, on the other hand, the MIC90s were > or = 4 micrograms/mL. There was no significant difference in fluoroquinolone susceptibility between methicillin-susceptible and -resistant S. epidermidis. Sparfloxacin, tosufloxacin, ciprofloxacin and levofloxacin were more active against enterococci. Most fluoroquinolones were relatively inactive against B. fragilis, with the exception of tosufloxacin, sparfloxacin and levofloxacin. The MIC90s of most quinolones assayed against K. pneumoniae, Citrobacter spp., E. cloacae, S. aureus and S. epidermidis were at least four-fold higher in our study. Therefore, it is important for physicians to use fluoroquinolones carefully so as to prevent or delay the emergence of resistant strains.

Anti-Infective Agents↗
PubMed1994

[Antibacterial activities of isepamicin against fresh clinical isolates of gram-negative bacilli].

To investigate antibacterial activities of isepamicin (ISP), MICs of ISP as well as other aminoglycosides (AGs) were determined against many strains of Gram-negative bacilli that were clinically isolated in 1993. 1. No ISP-resistant strains were observed among isolates of Escherichia coli, Citrobacter diversus, Klebsiella spp., Enterobacter spp. or Proteus mirabilis. 2. ISP-resistant strains were observed among isolates of Citrobacter freundii, Serratia spp., Proteus vulgaris, Morganella morganii, Providencia spp. and Pseudomonas aeruginosa. The frequency of resistant strains in each species, however, was lower for ISP than other AGs. 3. When MIC90s were compared, antibacterial activities of ISP determined in this study were quite similar to those determined during the drug's development period (1980's) in Japan, suggesting no increase in the number of ISP-resistant strains over the years. 4. The number of clinically isolated Gram-negative bacilli resistant to multiple drugs are increasing in from year to year Japan. Our results in this study suggest that antibacterial activities of ISP may be potent enough against such Gram-negative bacilli resistant to multiple drugs.

Drug Resistance, Microbial↗
PubMedDate not supplied

On the serological relationship between Salmonella O-groups 48 and 64 and the corresponding Arizona O-groups 5 and 29 which would justify a merger of these groups.

In 1963 Kauffmann divided O-group Y (O:48) of the Kauffmann-White schema into 3 sub-groups, e.g. 48(1),48(2) (S. dahlem), 48(1),48(2),48(3) (S. djakarta), 48(1),48(3),48(4) (Citrobacter 2624/36). He also recommended the use of the two serotypes S. dahlem and S. djakarta for the preparation of a diagnostic group-serum. At that time, serological relations--especially O-antigenic relations (and even some identities)--between the separate Salmonella and Arizona genera were known, viz. between the Salmonella group O:48 and the Arizona group O:5. It has now been found that there exist also close serological relations between the Salmonella O-groups 48 and 64 on the one hand and to the corresponding Arizona O-groups 5 and 29 on the other hand, in connection with which the special factor 48(4) defined by Kauffmann in the Citrobacter culture 2624/36 enbraces the whole Salmonella group O:64 (Arizona group O:29). Therefore, every Salmonella O:64 strain and Arizona O:29 serotype respectively can be agglutinated with factor-serum 48(4), defined by Kauffmann. A special O:64 serum is no longer required. The Salmonella antigen 64 (Arizona O:29 or O:5,29) has as a rule the partial antigens 48(1),48(3),48(4) (Arizona O:29). Only a few serotypes do not possess factor 48(3): their components are 48(1) and 48(4) (Arizona O:29). The evidence of our findings demonstrates that the Salmonella O-group 64 (Arizona O:29) should be combined with O-group 48 (Arizona O:5) and erased from the original Kauffmann-White schema and the Arizona antigenic schema to avoid a wrong diagnosis.

Agglutination Tests↗
PubMed1993

[Antimicrobial activity of cefodizime against fresh clinical isolates].

In order evaluate antimicrobial activities of cefodizime (CDZM), minimum inhibitory concentrations (MIC's) of CDZM and other control drugs were determined against various clinical isolates, that were sent to our center from nation-wide medical institutions or were isolated and identified in our laboratory from various specimens of infected patients. The followings are a summary of the results: 1. Bacterial species with no or few strains resistant to cephems including CDZM included Streptococcus pyogenes, Haemophilus influenzae, Citrobacter diversus, most of Klebsiella pneumoniae and Proteus mirabilis. Some strains of Klebsiella oxytoca were resistant to cephems increases in beta-lactams resistant Streptococcus pneumoniae and cephem resistant Escherichia coli seemed likely. Among Citrobacter freundii, Enterobacter spp., Serratia marcescens, Proteus vulgaris, Morganella morganii and Providencia spp. belonging to a category of so-called "mildly toxic bacteria", high portions of the strains examined were resistant to cephems including CDZM and these strains were also resistant to new quinolones, thus they showed multiple drug resistance. 2. MIC90's of CDZM against Streptococcus spp., H. infleunzae, Moraxella subgenus Branhamella catarrhalis, E. coli, Klebsiella spp. and P. mirabilis, frequently found in daily treatment of infections, were less than < or = 0.025 to 1.56 micrograms/ml. This indicates that CDZM would be expected to have enough antibiotic activity in infections caused by above mentioned bacteria. However, cautions are needed in the treatment of infections by beta-lactam resistant S. pneumoniae, cephem resistant E. coli and cephem resistant K. oxytoca with CDZM. 3. Among the above mentioned "mildly toxic bacteria", many multiple drug resistant strains exist. Therefore, we evaluated an usefulness of concomitant use of CDZM with aminoglycosides in the treatment of infections by these bacteria, using other reports which indicates the usefulness in vitro and in vivo. 4. Antibacterial activities of CDZM we observed in this study seem to indicate that CDZM concentrations in infected areas are maintained at above MIC levels for relatively long periods of time.

Bacteria↗
PubMedDate not supplied

[Oral ofloxacin versus intramuscular ceftriaxone in antibiotic prophylaxis in transurethral prostate resection].

This randomized prospective study evaluated the safety and efficacy of a single oral dose of OFL compared to a single parenteral dose of CTRX prior to TURP. 191 patients (mean age: 68.7 +/- 6.2 years) with bacterial free urine before surgery were enrolled and received either OFL: 400 mg per os (n = 95) or CTRX: 1 g intrasmuscularly (n = 96) at the pre-anaesthetic medication time (two hours prior TURP). Two urine cultures were obtained: on the day of the patient's discharge and within one month after surgery. Blood cultures were performed in case of temperature > 38 degrees 5C. Treatment failure was defined as bacteriuria > 10(5) CFU/ml and/or in case of positive blood culture after surgery. 182 patients were evaluable for efficacy. They were similar with respect to age, prostatic resection, histology, duration of post operative catheterization in the two treatment groups. On discharge from the department, 93.2% of the patients in the OFL group had sterile urines versus 94.6% in the CTRX group. In failure, causative pathogens were in the OFL group: 3 enterococcus, 1 acinetobacter, 1 staphylococcus, 1 citrobacter; in the CTRX group: 1 acinetobacter, 2 citrobacters, 1 enterococcus, 1 streptococcus. No bacteremia occurred. After one month of follow-up, 171 patients were evaluable (success on discharge from the department): the rates of success were: 93.5% in the OFL group and 90.3% in the CTRX group. Tolerance was good in both groups. These two drugs are as effective and as well tolerated for prevention of post operative UTI in TURP. But Ofloxacin is cost effective and simplest for use.

Administration, Oral↗